David A. Siegel Aprea Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$4.05 - $5.5 $1.37 Million - $1.86 Million
-338,700 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$4.73 - $8.15 $1.47 Million - $2.54 Million
311,600 Added 1149.82%
338,700 $1.73 Million
Q4 2020

Feb 16, 2021
BUY
$4.92 - $30.67 $133,332 - $831,157
27,100 New
27,100 $133,000

Others Institutions Holding APRE

# of Institutions
3
Shares Held
999
Call Options Held
0
Put Options Held
0
View Full List

About Aprea Therapeutics, Inc.

APRE Quotes by TradingView
  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email